• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
XIAO Yanan, SUN Jianguo, WAN Ping, WANG Guangji. Pharmacokinetics of(S)-ornidazole and(S)-ornidazole phosphate disodium in rats[J]. Journal of China Pharmaceutical University, 2014, 45(5): 571-575. DOI: 10.11665/j.issn.1000-5048.20140512
Citation: XIAO Yanan, SUN Jianguo, WAN Ping, WANG Guangji. Pharmacokinetics of(S)-ornidazole and(S)-ornidazole phosphate disodium in rats[J]. Journal of China Pharmaceutical University, 2014, 45(5): 571-575. DOI: 10.11665/j.issn.1000-5048.20140512

Pharmacokinetics of(S)-ornidazole and(S)-ornidazole phosphate disodium in rats

More Information
  • The aims of this study were to conduct the comparative evaluation of pharmacokinetic of(S)-ornidazole [(S)-ONZ] and(S)-ornidazole phosphate disodium [(S)ONZ-P] in rats, and to observe the potential chiral transformation to(R)-ornidazole [(R)-ONZ] using developed LC-MS/MS method. After single, intravenous administration of 25, 50, 100 mg/kg(S)-ONZ and(S)-ONZ-P [equal molarity to that of(S)-ONZ], it was found that there existed linearity between the calculated areas under the curve(AUC0-∞)and dose. And elimination half-time(t1/2 )of(S)-ONZ was calculated to be 2. 04-2. 31 h and 2. 02-2. 51 h, respectively. After iv dosing of(S)-ONZ-P, (S)-ONZ-P quickly transferred into(S)-ONZ with the average transformation time of around 1. 57 to 3. 86 min. No significant differences in pharmacokinetics between the two drugs were found in rats. There was no(R)-ONZ detected in the plasma using both(S)-ONZ and(S)-ONZ-P.
  • [1]
    Huttunen KM,Raunio H,Rautio J.Prodrugs—from serendipity to rational design[J].Pharmacol Rev,2011,63(3):750-771.
    [2]
    Zawilska JB,Wojcieszak J,Olejniczak AB.Prodrugs:a challenge for the drug development[J].Pharmacol Rep,2013,65(1):1-14.
    [3]
    Stella VJ.Prodrugs:some thoughts and current issues[J].J Pharm Sci,2010,99(12):4 755-4 765.
    [4]
    Scott FI,Osterman MT.Medical management of Crohn disease[J].Clin Colon Rectal Surg,2013,26(2):67-74.
    [5]
    Papi C,Fasci SF,Margagnoni G,et al.Randomized controlled trials in prevention of postsurgical recurrence in Crohn′s disease[J].Rev Recent Clin Trials,2012,7(4):307-413.
    [6]
    Chen K,Sun JH,Wang,ZQ,et al.Different mechanism between ornidazole enantiomers on central nervous system in mice[J].J China Pharm Univ(中国药科大学学报),2012,43(3):271-274.
    [7]
    Jana S,Mandlekar S,Marathe P.Prodrug design to improve pharmacokinetic and drug delivery properties:challenges to the discovery scientists[J].Curr Med Chem,2010,17(32):3 874-3 908.
    [8]
    Marat DM,Romari Am,Mariela N,et al.Biomarkers of genotoxicity and genomic instability in a non-human primate,Cebus libidinosus (Cebidae,Platyrrhini),exposed to nitroimidazole derivatives[J].Mutat Res,2011,721(1):108-113.
    [9]
    Menendez D,Rojas E,Herrera LA,et al.DNA breakage due to metronidazole treatment[J].Mutat Res,2001,478(1/2):153-158.
    [10]
    Muller J,Schildknecht P,Muller N.Metabolism of nitro drugs metronidazole and nitazoxanide in Giardia lamblia:characterization of a novel nitroreductase(GlNR2)[J].J Antimicrob Chemother,2013,68(8):1 781-1 789.
    [11]
    Lopez NMM,Palermo AM,Mudry MD,et al.Cytogenetic evaluation of two nitroimidazole derivatives[J].Toxicol In Vitro,2003,17(1):35-40.
    [12]
    Zhu YC,Sun JG,Peng Y,et al.Research on the pharmacokinetics of prodrug[J].Chin J Clin Pharmacol Ther(中国临床药理学与治疗学),2012,(12):1 433-1 440.
    [13]
    Feng D,Sun JG,Zhu YC,et al.Pharmacokinetics of a novel antihypertension candidate ATPT in Beagle dogs[J].J China Pharm Univ(中国药科大学学报),2013,44(2):151-155.
    [14]
    Duan YB, Zhang SB, Liu S, et al. Study on pharmacokinetics methodlogy of S-(-)oornifazol disodium phosphate[J].J Southeast Univ(Med Sci Ed)(东南大学学报 医学版),2011,30(2):312-315.

Catalog

    Article views (1572) PDF downloads (1879) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return